PART 2 ADDITONAL NOTEWORTHY AGENTS
The FDA approved 40 new drugs and biologics of note in 2013. Eight are first-in-class agents indicated for the management of a variety of conditions (see part 1 of this series). Among the remainder are 22 newly approved drugs that are pharmacologically similar to others already marketed (see Table 69-3) and 10 new biologics. Although draft guidance on biosimilar product development was published by FDA in 2012, to date there have been no "follow-on biologics" approved in the U.S. under the new rules.1 On another note, the FDA Safety and Innovation Act of 2012 had a dramatic impact on pediatric drug approvals in 2013.2,3 The Act permanently reauthorized the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA).4,5 Together, these two companion laws provide for an incentive (6 months of marketing exclusivity) and extend federal authority to enforce FDA requirements that drugs used in pediatric populations be reviewed for safety and efficacy. Supplemental pediatric indications were approved for at least 34 new and existing drugs and biologics in 2013.6,7,8,9,10,11 Other 2013 noteworthy FDA regulatory activities are summarized below. Table 69-4 lists established drugs that were "repurposed" for a new indication or significantly reformulated in 2013.
Table 69-3.New Drugs Licensed in 2013 with Pharmacological Mechanisms Similar to Previously Approved Drugs |Favorite Table|Download (.pdf) Table 69-3. New Drugs Licensed in 2013 with Pharmacological Mechanisms Similar to Previously Approved Drugs
|Generic Name ||Brand Name ||Pharmacology ||FDA Approved Indication ||Pharmacologically Similar Agents ||Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12e Reference |
|ado-trastuzumab emtansine ||kadcyla ||HER2-targeted antibody-microtubule inhibitor conjugate ||HER2––positive, metastatic breast cancer ||trastuzumab ||Chapter 62. Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal Antibodies, and Cytokines |
|afatinib† ||gilotrif || |
tyrosine kinase inhibitor
(EGFR, HER2, HER4)
|non––small cell lung cancer ||erlotinib, lapatinib, vandetanib ||Chapter 62. Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal Antibodies, and Cytokines |
|alogliptin§ ||nesina ||dipeptidyl peptidase-4 (DPP-4) inhibitor ||type 2 diabetes mellitus ||linagliptin, saxagliptin, sitagliptin ||Chapter 43. Endocrine Pancreas And Pharmacotherapy Of Diabetes Mellitus And Hypoglycemia > DPP-4 Inhibitors (see DPP-4 Inhibitors – An Update on Alogliptin in Goodman & Gilman Online Updates) |
|bazedoxifene [marketed in combination with conjugated estrogens] ||Duavee ||selective estrogen receptor modulator [marketed in combination with conjugated estrogens] ||post-menopausal osteoporisis prevention; vasomotor symptoms ||ospemifene, raloxifene, tamoxifen, toremifene ||Chapter 40. Estrogens and Progestins |
|dabrafenib† ||tafinlar ||BRAF inhibitor ||melanoma with the BRAF V600E gene mutation ||vemurafenib ||Chapter 62. Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal Antibodies, and Cytokines |
|dolutegravir ||tivicay ||HIV-1 integrase inhibitor ||HIV-1 infection ||raltegravir ||Chapter 59. Antiretroviral Agents and Treatment of HIV Infection >Integrase Inhibitors |
|eslicarbazepin† ||aptiom ||iminostilbene anticonvulsant ||partial-onset seizures || |
|Chapter 21. Pharmacotherapy of the Epilepsies > Iminostilbenes |
|ferric carboxymaltose ||injectafer ||iron supplement ||iron-deficiency anemia ||erumoxytol, iron dextran, iron sucrose, sodium ferric gluconate complex ||Chapter 37. Hematopoietic ...|
Pop-up div Successfully Displayed
This div only appears when the trigger link is hovered over.
Otherwise it is hidden from view.